The glycemic efficacy of tirzepatide in the treatment of T2DM was found to be due to simultaneous improvements in key components of diabetes pathophysiology, including beta-cell function, insulin sensitivity, and glucagon secretion, in Phase 1 clinical trials [131]. The gene discussed is INS; the disease is type 2 diabetes mellitus.